ACTIVE IMMUNOTHERAPY WITH A POLYVALENT MELANOMA VACCINE IN STAGE III

III 期多价黑色素瘤疫苗的主动免疫治疗

• 批准号: 7377397
• 负责人: DAVID W OLLILA
• 金额: $ 1.49万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377397
• 关键词: ACTIVE; IMMUNOTHERAPY; POLYVALENT; MELANOMA; VACCINE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine whether BCG, a germ found in tuberculosis, in combination with melanoma vaccine (C-VAX) is more effective than BCG and a placebo in 1) stimulation of immune response against melanoma, 2) improving overall survival, and 3) causing a delay in recurrence following surgery. This research is being done because there is no currently approved treatment for melanoma, which prolongs survival time, and no treatment of melanoma, which prolongs the time to recurrence, that does not have significant side effects. It is hoped that the combination of BCG and C-VAX, an experimental test drug will have benefits, which will help solve thi

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项研究的目的是确定BCG（一种在结核病中发现的细菌）与黑色素瘤疫苗（C-VAX）联合使用是否比BCG和安慰剂更有效：1）刺激对黑色素瘤的免疫反应，2）提高总生存率，3）导致手术后复发延迟。这项研究正在进行，因为目前没有批准的治疗黑色素瘤，这缩短生存时间，也没有治疗黑色素瘤，这缩短复发时间，没有显着的副作用。人们希望BCG和C-VAX（一种实验性测试药物）的组合将产生益处，这将有助于解决这一问题。